Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Less Than Half of Incarcerated Population Receives Recommended Cancer Care

November 20, 2025
By Cary Gross, MD
Commentary
Video

A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.

Although about a third of the general population may not receive guideline-concordant care for cancer, more than half of patients incarcerated or recently released did not receive recommended care, highlighting severe gaps in accessing effective treatment among these populations.

In an interview with CancerNetwork®, Cary P. Gross, MD, professor of General Medicine and Epidemiology, as well as the founder and director of the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at the Yale School of Medicine, discussed findings from a study he coauthored and published in JAMA Network Open. The study explored the disparities in the quality of care between the general population and currently or recently incarcerated individuals undergoing treatment for their cancers.

Gross began by highlighting a relationship between history of incarceration and a lower quality of care among patients undergoing cancer treatment, with 49% of patients who were incarcerated at cancer diagnosis and 45% of those diagnosed within 1 year of release receiving guideline-concordant care vs 67% of the general population. Furthermore, Gross postulated that among all populations, there is a significant need for greater access to quality care, and that for the incarcerated population his team examined, underlying challenges related to accessing care and social determinants of health may could present as barriers.

Transcript:

What we found was that there was a relation between incarceration history and the quality of care. What we did was we matched [patients] who had been diagnosed with cancer in a certain time frame according to where they were diagnosed. What we found was that, broadly speaking, [for] people who were diagnosed during incarceration, about half of them received the care that was recommended for them [across] different types of cancer, breast, lung, prostate, et cetera; half of [patients] diagnosed during incarceration. But we found amongst people who were incarcerated but diagnosed afterward—the year after incarceration—only 45% were getting the recommended care. Both of those groups, 49% while incarcerated [and] 45% after incarceration, ended up having a lower likelihood of getting recommended care than people who are diagnosed out in the community; that group was 67%.

There are 2 main findings [or] 2 main inferences here. First, if you leave incarceration, leave that bucket to the side for a second, and focus on the broader population here in Connecticut, 67% [or] only two-thirds of [patients] are getting all of the care that’s recommended for them. [With] guideline-concordant care overall in the general population, there’s plenty of room for improvement. Now, the other 2 groups [with] current or recent incarceration, both of them had a lower quality of care, and that suggests that maybe it’s not the issue of whether someone’s currently incarcerated; maybe the underlying social challenges and challenges [with] accessing health care that may be associated with incarceration are driving some of these challenges to access and care.

Two take home points: there is a relation between incarceration and lower quality of care, but it’s not just because you are incarcerated. Again, because we think that the same factors that are associated with incarceration—such as less likelihood of having health insurance or being exposed to racism, a lack of feeling comfortable or welcome, or obtaining high quality care in the health system—could be barriers. The other major take home point is that in the larger population, there are gaps for everyone in getting the quality of care that [they] need.

Reference

Oladeru OT, Richman IB, Aminawung JA, et al. Incarceration and quality of cancer care. JAMA Netw Open. 2025;8(10):e2537400. doi:10.1001/jamanetworkopen.2025.37400

Recent Videos
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Related Content
Advertisement

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High-Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.


Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.


Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas

Ariana Pelosci
November 19th 2025
Article

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data

Russ Conroy
November 16th 2025
Article

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.


There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

Tim Cortese
November 15th 2025
Article

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Related Content
Advertisement

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High-Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.


Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.


Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.

FDA OKs Selumetinib in NF1 Symptomatic, Inoperable Plexiform Neurofibromas

Ariana Pelosci
November 19th 2025
Article

Results from the KOMET trial led to the approval of selumetinib in adults with NF1 symptomatic, inoperable plexiform neurofibromas.


Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.


A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data

Russ Conroy
November 16th 2025
Article

A busy week for the FDA saw notable regulatory approvals across different breast cancer, acute myeloid leukemia, and endometrial cancer indications.


There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer

Tim Cortese
November 15th 2025
Article

There is a lot of excitement among experts in the field of antibody-drug conjugates as new developments continue to come out in various disease states.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.